The Federal Circuit’s disposition — ‘We have considered Alnylam’s remaining arguments and find them unpersuasive. We affirm the decision of the district court’ — is notable for its directness. At the appellate level, the court applies a deferential standard to factual findings (clear error) while reviewing claim construction and legal conclusions de novo. The panel’s categorical dismissal of all remaining arguments, without remand or qualification, suggests Alnylam’s positions failed under both standards. The word ‘remaining’ implies earlier arguments were addressed in the body of the opinion, reinforcing the substantive depth of the court’s analysis.

Any organisation developing or commercialising mRNA-based products — including vaccines, oncology therapeutics, rare disease treatments, or gene editing platforms — that uses lipid nanoparticle delivery systems should assess exposure to Alnylam’s LNP portfolio. While the Federal Circuit’s affirmance resolves these patents as applied to SPIKEVAX®, the patents remain in force and may be asserted against different product formulations or distinct mRNA applications. The district court’s claim constructions are now reinforced by the appellate decision, making this a critical moment to map your LNP formulations against upheld claim scope.

PatSnap Eureka’s FTO Search Agent can map US11246933B1 and US11382979B2 against your specific LNP formulation parameters, identify claim elements most likely to read on your platform, and surface related Alnylam continuation filings that may present future risk. Eureka also tracks prosecution history and file wrapper data for both application numbers — 17/302311 and 17/644907 — providing the granular claim-level insight that product and IP teams need before advancing to clinical or commercial stage.